Onconetix, Inc.(ONCO)Earnings, Financials & Key RatiosOnconetix, Inc. (ONCO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
Negative: The company's precarious $3.7 million cash position against a $4.2 million quarterly net loss in 2026Q1 indicates an imminent risk of insolvency.
Onconetix, Inc. (ONCO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Onconetix, Inc. (ONCO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $6.71 | $21,457 |
| Q2 2026 | Mar 12, 2026 | $12.58 | $303,596 |
| Q4 2025 | Nov 13, 2025 | $6.25 | $303,651 |
| Q3 2025 | Aug 14, 2025 | $4.05 | $106,494 |
Recent stock market news and headlines for Onconetix, Inc. (ONCO)
Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.
VANCOUVER, BC / ACCESS Newswire / June 23, 2026 / Onco-Innovations Limited (NEO:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a services agreement with Nanosoft Polymers ("Nanosoft"), a specialized polymer engineering and drug delivery company, to support the continued development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor. Under the agreement, Nanosoft will provide polymer process development, analytical characterization, scale-up support, formulation optimization, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform.
Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Private Placement") of units of the Company (each, a "Unit"), pursuant to which it will offer 6,764,069 Units at a price of CAD$0.7392 per Unit for aggregate gross proceeds of approximately CAD$5,000,000 pursuant to the Listed Issuer Financing Exemption (as defined below). Each Unit is comprised of one common share (each a "Share") and one common share purchase warrant (a "Warrant"), with each Warrant entitling the holder to purchase one Share at a price of CAD$0.90 for a period of three years following the closing date of the Private Placement, which is expected to occur on or about July 10, 2026, subject to certain conditions, including the receipt of all necessary regulatory approvals, including the approval of Cboe Canada Inc. (the "Cboe").
Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "Company") announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient ("API") underpinning the Company'sproprietary drug candidate, ONC010 (the "PNKP Inhibitor Technology").
VANCOUVER, BC / ACCESS Newswire / June 16, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated November 18, 2025, the completion of its pilot project with Kuano Ltd. ("Kuano"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches.
Key metrics vs top competitors for Onconetix, Inc. (ONCO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.07 | $672.52K | -0.23 | -67.7% | -1720.98% | -110.6% | — | |
| $15.63 | $1.31B | -29.49 | — | — | -38.92% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Onconetix, Inc. (ONCO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Onconetix, Inc. (ONCO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 19, 2026·SEC
May 14, 2026·SEC
May 4, 2026·SEC
Get notified when ONCO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Onconetix, Inc. (ONCO) stock FAQ — growth, dividends, profitability & financials explained
Onconetix, Inc. (ONCO) reported $0.7M in revenue for fiscal year 2025.
Onconetix, Inc. (ONCO) saw revenue decline by 67.7% over the past year.
Onconetix, Inc. (ONCO) reported a net loss of $9.7M for fiscal year 2025.
Onconetix, Inc. (ONCO) has a return on equity (ROE) of -110.6%. Negative ROE indicates the company is unprofitable.
Onconetix, Inc. (ONCO) had negative free cash flow of $9.8M in fiscal year 2025, likely due to heavy capital investments.
